MedTrace Logo

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

NCT01632540 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 824

Last updated 2014-04-15

No results posted yet for this study

Summary

This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly online surveys regarding rhinitis control, concomitant medical conditions, concomitant (non-AR) medications, current AR therapy, and adverse events.

Conditions

  • Perennial Allergic Rhinitis (PAR)

Interventions

DRUG

Beclomethasone Dipropionate (BDP) Nasal Aerosol

BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.

Sponsors & Collaborators

  • United BioSource, LLC

    collaborator INDUSTRY

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Lepore, MD · Teva Pharmaceutical Industries, Ltd.

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-12-31
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632540 on ClinicalTrials.gov